GSK drug shows promise in treating anaemia in kidney disease patients

Reuters2021-07-16

July 16 (Reuters) - GlaxoSmithKline Plc said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage experimental trials, marking an important milestone for the British ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Alfred1007
2021-07-17
Alfred1007
Hope this is a comeback for long sleeping giant...
KarWaiLoh
2021-07-16
KarWaiLoh
Insightful
Kencom
2021-07-16
Kencom
It is a new breakthrough to bring GSK to the next leap translate into higher revenue & profits.
- PeterPuah1:
  good
MrInvestor
2021-07-16
MrInvestor
Show promise not equal to effective but it's a good sign
Imgoh
2021-07-16
Imgoh
Good news
Angelinetang
2021-07-16
Angelinetang
Like

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2151504161?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-16 20:12","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2151504161","market":"us","top_or_hot":-1,"title":"GSK drug shows promise in treating anaemia in kidney disease patients","media":"Reuters","content":"<div>\n<p>July 16 (Reuters) - GlaxoSmithKline Plc said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage experimental trials, marking an important milestone for the British ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-gsk-drug-shows-promise-121218995.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK drug shows promise in treating anaemia in kidney disease patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK drug shows promise in treating anaemia in kidney disease patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 20:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-gsk-drug-shows-promise-121218995.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 16 (Reuters) - GlaxoSmithKline Plc said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage experimental trials, marking an important milestone for the British ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-gsk-drug-shows-promise-121218995.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"https://finance.yahoo.com/news/1-gsk-drug-shows-promise-121218995.html","article_id":"2151504161","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2151504161","pubTimestamp":1626437538,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"July 16 (Reuters) - GlaxoSmithKline Plc said on Friday its anaemia drug for patients with kidney dis","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK":"葛兰素史克","AZN":"阿斯利康"},"translate_title":"葛兰素史克药物有望治疗肾病患者贫血","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":0.9,"AZN":0.6},"content_text":"July 16 (Reuters) - GlaxoSmithKline Plc said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage experimental trials, marking an important milestone for the British drugmaker as it bolsters its pipeline of new drugs.\nThe drug, daprodustat, belongs to a new class of medicines that works by copying the body's response to hypoxia, or low oxygen levels, and boosts production of red blood cells by mimicking the body's response to high altitude.\nGSK said results from five late stage studies showed the drug improved haemoglobin levels in patients who had not received any standard care, and helped maintain the levels in those who did.\nDaprodustat was also well-tolerated in both dialysis and non-dialysis patients.\nA rival drug roxadustat, developed by AstraZeneca and Fibrogen, works just like GSK's treatment and won its first approval in China in late 2018, but a panel of experts to U.S. authorities voted against its approval on Thursday.\nGSK's daprodustat is currently approved only in Japan for use in patients with renal anaemia.\nAnaemia is a condition in which the number of red blood cells, or haemoglobin concentration within them, is lower than normal, and can commonly affect patients with kidney disease.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":179285805,"gmtCreate":1626534434407,"gmtModify":1703761533395,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":0,"idStr":"3570656625926041","authorIdStr":"3570656625926041"},"htmlText":"Hope this&nbsp;is a comeback for long sleeping giant...","listText":"Hope this&nbsp;is a comeback for long sleeping giant...","text":"Hope this is a comeback for long sleeping giant...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/179285805","repostId":2151504161,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":170542146,"gmtCreate":1626444066385,"gmtModify":1703760312874,"author":{"id":"3585045414220324","authorId":"3585045414220324","name":"KarWaiLoh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585045414220324","authorIdStr":"3585045414220324"},"htmlText":"Insightful","listText":"Insightful","text":"Insightful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170542146","repostId":2151504161,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":170538405,"gmtCreate":1626441700807,"gmtModify":1703760222807,"author":{"id":"4088748055325860","authorId":"4088748055325860","name":"Kencom","avatar":"https://community-static.tradeup.com/news/bcaa9548fb78e0409a2827c590935dab","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"4088748055325860","authorIdStr":"4088748055325860"},"htmlText":"It is a new breakthrough to bring GSK to the next leap translate into higher revenue &amp; profits.&nbsp;","listText":"It is a new breakthrough to bring GSK to the next leap translate into higher revenue &amp; profits.&nbsp;","text":"It is a new breakthrough to bring GSK to the next leap translate into higher revenue & profits.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/170538405","repostId":2151504161,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5240272,"gmtCreate":1626442770602,"gmtModify":1663231063258,"authorId":3581997712122613,"author":{"id":3581997712122613,"idStr":"3581997712122613","authorId":3581997712122613,"name":"PeterPuah1","avatar":"https://static.tigerbbs.com/6485f820255455f8ea6dc07c9e457062","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":170538405,"type":1,"supId":0,"prevId":0,"content":"<u>good</u>","text":"<u>good</u>","html":"<u>good</u>"}],"langContent":"EN"},{"id":170538271,"gmtCreate":1626441691893,"gmtModify":1703760222644,"author":{"id":"3586672191897597","authorId":"3586672191897597","name":"MrInvestor","avatar":"https://static.tigerbbs.com/40974a38cd623c0089adf8fd12d91591","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586672191897597","authorIdStr":"3586672191897597"},"htmlText":"Show promise not equal to effective but it's a good sign","listText":"Show promise not equal to effective but it's a good sign","text":"Show promise not equal to effective but it's a good sign","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170538271","repostId":2151504161,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":170277404,"gmtCreate":1626440028508,"gmtModify":1703760187755,"author":{"id":"3581825520109338","authorId":"3581825520109338","name":"Imgoh","avatar":"https://static.tigerbbs.com/37ecbebf2e324891c637f8afc0232f89","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581825520109338","authorIdStr":"3581825520109338"},"htmlText":"Good news&nbsp;","listText":"Good news&nbsp;","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170277404","repostId":2151504161,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":170273258,"gmtCreate":1626439598374,"gmtModify":1703760177517,"author":{"id":"3562110654160486","authorId":"3562110654160486","name":"Angelinetang","avatar":"https://static.tigerbbs.com/db70c1a81c4a4398c4b43ef2d5c8c35d","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3562110654160486","authorIdStr":"3562110654160486"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170273258","repostId":2151504161,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":49,"commentSize":8,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2151504161"}